By


Ride Health Raises $10 Million to Scale National Medical Transportation Platform 

Company brings real-time visibility to the non-emergency medical transportation industry, improving access to care and social resources for underserved populations 

See more here

By


InfraScan Inc. Announces DoD/DHA Product Development Partnership 

InfraScan announces product development partnership with DoD

See more here

By


Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors 

– Dr. Prendergast is a renowned scientific researcher with over 45 years of association with the Mayo Foundation and over 20 years’ experience as a non-executive director of Eli Lilly

See more here

By


Ossianix Announces Publication of Positive Preclinical Data on Neutralizing SARS-CoV-2 Infection with a Panel of Single Domain Shark VNAR Antibodies

A highly potent panel of VNARs against the SARS-CoV-2 spike protein has been isolated

Neutralization of SARS-CoV-2 was demonstrated in in vitro infectivity assays

In vitro blocking activities were also found against the N501Y and E484K mutants

See more here

By


Melior Pharmaceuticals Announces Entry Into “Letter-of-Intent” for the Acquisition of Armesocarb by Adhera Therapeutics 

  • Under the terms of the intended acquisition:  
    • Adhera will continue clinical development of MLR-1019
    • Melior Pharmaceuticals will receive Adhera stock plus royalties

See more here

By


Renovacor Announces the Appointment of Marc Semigran, M.D., as Chief Medical Officer

Former chief medical officer of MyoKardia to lead clinical development at Renovacor 

See more here

By


Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern

– Additional $4.3 million in funding brings total DOD funding to $17.6 million.

– Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.

– Neutralizes South Africa (B.1.351) and UK (B.1.1.7) in live virus testing and Brazil (P.1) and California (B.1.429, also containing B.1.427 mutations) in pseudovirus testing, all of which are CDC-designated “Variants of Concern.”

– Binds to several mutations, including E484Q and L452R, which are associated with the India variant (B.1.617) in mechanistic testing.

See more here

By


Annovis Bio Appoints Accomplished Neuroscientist Dr. Cheng Fang as VP of Research

See more here